PROTEASOME INHIBITION: RECENT ADVANCES IN ANTITUMORAL THERAPY
ELENA CAMELIA STĂNCIULESCU1, CĂTĂLINA GABRIELA PISOSCHI1*, GABRIELA RĂU1, ANA-MARINA ANDREI1, MONICA BANIȚĂ2
1Faculty of Pharmacy, 2Faculty of Dentistry,
University of Medicine and Pharmacy of Craiova, Romania
* corresponding author: c_pisoschi@yahoo.com
DownloadDownload Full Article

Abstract:

The major pathway for degradation of intracellular proteins is the ubiquitin-proteasome pathway. There is increasing evidence revealing that the dysregulation of the ubiquitin-proteasome pathway are involved in pathogenesis of many diseases such as cancer and neurodegenerative disorders. Many studies are focused now on developing new drugs that target ubiquitin-proteasome pathway, based on the observation that proteasome inhibition induces apoptosis in many tumor cells.
This review exposes recent data concerning the use of proteasome inhibitors in cancer therapy.






Top